Literature DB >> 18950747

Delta-opioid receptor antagonists prevent sensitization to the conditioned rewarding effects of morphine.

Toni S Shippenberg1, Vladimir I Chefer, Alexis C Thompson.   

Abstract

BACKGROUND: Functional interactions between mu- and delta-opioid receptors (MOPr and DOPr, respectively) are implicated in morphine tolerance and dependence. The contribution of DOPr to the conditioned rewarding effects of morphine and the enhanced conditioned response that occurs after repeated morphine administration is unknown. This issue was addressed with the conditioned place preference procedure (CPP).
METHODS: Rats received home cage injections of saline or morphine (5.0 mg/kg/day x 5 days) before conditioning. For sensitization studies, DOPr antagonists (DOPr1/2: naltrindole, DOPr2: naltriben, DOPr1: 7-benzylidenenaltrexone) were administered before morphine injections. Conditioning sessions (2 morphine; 2 saline) commenced 3 days later. To assess the influence of acute DOPr blockade on the conditioning of morphine reward in naïve animals, 3 morphine and 3 saline conditioning sessions were employed. Antagonists were administered before morphine conditioning sessions.
RESULTS: Morphine was ineffective as a conditioning stimulus after two conditioning sessions in naïve rats. However, doses > or = 3.0 mg/kg produced significant CPP in morphine pre-exposed rats, confirming that sensitization develops to the conditioned rewarding effects of morphine. In animals that received morphine pre-exposure with naltrindole or naltriben but not 7-benzylidenenaltrexone, sensitization was prevented. No attenuation of morphine CPP was observed in animals that received DOPr antagonists acutely, before conditioning sessions.
CONCLUSIONS: These data indicate a critical role of DOPr systems in mediating sensitization to the conditioned rewarding effects of morphine. The efficacy of naltrindole and naltriben in preventing the enhanced response to morphine suggest the specific involvement of DOPr2 in the sensitization process.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18950747      PMCID: PMC3832215          DOI: 10.1016/j.biopsych.2008.09.009

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  44 in total

1.  A bivalent ligand (KDN-21) reveals spinal delta and kappa opioid receptors are organized as heterodimers that give rise to delta(1) and kappa(2) phenotypes. Selective targeting of delta-kappa heterodimers.

Authors:  Rashmi G Bhushan; Shiv K Sharma; Zhihua Xie; David J Daniels; Philip S Portoghese
Journal:  J Med Chem       Date:  2004-06-03       Impact factor: 7.446

2.  Selective blockage of delta opioid receptors prevents the development of morphine tolerance and dependence in mice.

Authors:  E E Abdelhamid; M Sultana; P S Portoghese; A E Takemori
Journal:  J Pharmacol Exp Ther       Date:  1991-07-01       Impact factor: 4.030

3.  Repeated exposures intensify rather than diminish the rewarding effects of amphetamine, morphine, and cocaine.

Authors:  B T Lett
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

Review 4.  Classical conditioning in drug-dependent humans.

Authors:  C P O'Brien; A R Childress; A T McLellan; R Ehrman
Journal:  Ann N Y Acad Sci       Date:  1992-06-28       Impact factor: 5.691

5.  Role of repeated exposure to morphine in determining its affective properties: place and taste conditioning studies in rats.

Authors:  M Gaiardi; M Bartoletti; A Bacchi; C Gubellini; M Costa; M Babbini
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

6.  Antinociception after intracerebroventricular administration of naltrindole in the mouse.

Authors:  A Stapelfeld; D L Hammond; M F Rafferty
Journal:  Eur J Pharmacol       Date:  1992-04-22       Impact factor: 4.432

7.  Antidepressant-type effects of endogenous enkephalins protected by systemic RB 101 are mediated by opioid delta and dopamine D1 receptor stimulation.

Authors:  A Baamonde; V Daugé; M Ruiz-Gayo; I G Fulga; S Turcaud; M C Fournié-Zaluski; B P Roques
Journal:  Eur J Pharmacol       Date:  1992-06-05       Impact factor: 4.432

8.  Differential antagonism of delta opioid agonists by naltrindole and its benzofuran analog (NTB) in mice: evidence for delta opioid receptor subtypes.

Authors:  M Sofuoglu; P S Portoghese; A E Takemori
Journal:  J Pharmacol Exp Ther       Date:  1991-05       Impact factor: 4.030

9.  Motivational properties of kappa and mu opioid receptor agonists studied with place and taste preference conditioning.

Authors:  R F Mucha; A Herz
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

10.  Agonist and antagonist activities of ligands derived from naltrexone and oxymorphone.

Authors:  A E Takemori; M Sultana; H Nagase; P S Portoghese
Journal:  Life Sci       Date:  1992       Impact factor: 5.037

View more
  36 in total

1.  Development and in vitro characterization of a novel bifunctional μ-agonist/δ-antagonist opioid tetrapeptide.

Authors:  Lauren C Purington; Katarzyna Sobczyk-Kojiro; Irina D Pogozheva; John R Traynor; Henry I Mosberg
Journal:  ACS Chem Biol       Date:  2011-10-11       Impact factor: 5.100

2.  Searching for evidence of genetic mediation of opioid withdrawal by opioid receptor gene polymorphisms.

Authors:  Jermaine D Jones; Rachel R Luba; Jonathan L Vogelman; Sandra D Comer
Journal:  Am J Addict       Date:  2015-12-21

3.  Orphanin FQ/nociceptin not only blocks but also reverses behavioral adaptive changes induced by repeated cocaine in mice.

Authors:  David Bebawy; Paul Marquez; Seroje Samboul; Drupad Parikh; Abdul Hamid; Kabirullah Lutfy
Journal:  Biol Psychiatry       Date:  2010-03-31       Impact factor: 13.382

4.  Upregulation of nerve growth factor in central amygdala increases sensitivity to opioid reward.

Authors:  Bihua Bie; Yan Wang; You-Qing Cai; Zhi Zhang; Yuan-Yuan Hou; Zhizhong Z Pan
Journal:  Neuropsychopharmacology       Date:  2012-08-08       Impact factor: 7.853

5.  The mixed kappa and delta opioid receptor agonist, MP1104, attenuates chemotherapy-induced neuropathic pain.

Authors:  Diana Vivian Atigari; Kelly Frances Paton; Rajendra Uprety; András Váradi; Amy Frances Alder; Brittany Scouller; John H Miller; Susruta Majumdar; Bronwyn Maree Kivell
Journal:  Neuropharmacology       Date:  2020-12-28       Impact factor: 5.250

6.  Modulation of opiate-related signaling molecules in morphine-dependent conditioned behavior: conditioned place preference to morphine induces CREB phosphorylation.

Authors:  José A Morón; Srinivas Gullapalli; Chirisse Taylor; Achla Gupta; Ivone Gomes; Lakshmi A Devi
Journal:  Neuropsychopharmacology       Date:  2009-12-02       Impact factor: 7.853

7.  Pentapeptides displaying mu opioid receptor agonist and delta opioid receptor partial agonist/antagonist properties.

Authors:  Lauren C Purington; Irina D Pogozheva; John R Traynor; Henry I Mosberg
Journal:  J Med Chem       Date:  2009-12-10       Impact factor: 7.446

8.  Functional impact of a single-nucleotide polymorphism in the OPRD1 promoter region.

Authors:  Huiping Zhang; Joel Gelernter; Jeffrey R Gruen; Henry R Kranzler; Aryeh I Herman; Arthur A Simen
Journal:  J Hum Genet       Date:  2010-03-19       Impact factor: 3.172

9.  Synthesis, modeling, and pharmacological evaluation of UMB 425, a mixed μ agonist/δ antagonist opioid analgesic with reduced tolerance liabilities.

Authors:  Jason R Healy; Padmavani Bezawada; Jihyun Shim; Jace W Jones; Maureen A Kane; Alexander D MacKerell; Andrew Coop; Rae R Matsumoto
Journal:  ACS Chem Neurosci       Date:  2013-06-11       Impact factor: 4.418

10.  Effect of Sinomenine on the Morphine-Dependence and Related Neural Mechanisms in Mice.

Authors:  Miao Fang; Junkui Li; Daoqi Zhu; Chaohua Luo; Chan Li; Chen Zhu; Menglin Fan; Ken Kin-Lam Yung; Zhixian Mo
Journal:  Neurochem Res       Date:  2017-11-08       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.